BAY 60-6583 NEW
| Price | $37 | $84 | $125 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-24 |
Product Details
| Product Name: BAY 60-6583 | CAS No.: 910487-58-0 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2025/10/24 |
Product Introduction
Bioactivity
| Name | BAY 60-6583 |
| Description | BAY 60-6583 is a potent, high-affinity adenosine A2B receptor agonist (EC50 = 3 nM) with affinity for A2B receptors that exceeds that for A1, A2A, and A3 receptors.BAY 60-6583 is cardioprotective in a model of myocardial ischemia.The Ki values for BAY 60-6583 binding to mouse, rabbit, and dog A2BAR were 750 nM, 340 nM, and 330 nM, respectively. The Ki values of BAY 60-6583 binding to A2BAR in mice, rabbits and dogs were 750 nM, 340 nM and 330 nM respectively. |
| In vitro | BAY 60-6583(0-10 μM) exhibits the maximum agonist effect of BAY 60-6583 in the absence of siRNA is 68 %.[3] BAY 60-6583 (5 μM; 24 h) induces a rise in cell accumulation within the G1 phase while concurrently reducing the G2/M phase in RAW264.7 preosteoclasts. Additionally, under the same conditions, BAY 60-6583 specifically impedes Akt activation triggered by M-CSF, with no discernible impact on M-CSF-induced ERK1/2 activation in RAW264.7 preosteoclasts.[4] |
| In vivo | BAY 60-6583 (100 mg/kg; intravenous injection; rabbit) administered just before reperfusion, diminishes the infarction area in ischemic rabbit hearts.[1] BAY 60-6583 (2 mg/kg; intravenous injection; mice) attenuates LPS-induced lung injury, pre-treatment with this compound can significantly decrease LPS-increased, IL-6 levels in WT mice.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90.0 mg/mL (237.2 mM), Sonication is recommended. |
| Keywords | BAY 60-6583 | BAY 606583 | BAY 60 6583 | AdenosineReceptor | Adenosine Receptor | A3 | A2B | A2A | A1 |
| Inhibitors Related | Theophylline monohydrate | Pentoxifylline | Diphylline | Acefylline | CPI-444 | Adenosine 5'-monophosphate monohydrate | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $729.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $37.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-10-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY